MétaCan
Menu
Back to cohort
Record W4409035768 · doi:10.1080/14796708.2025.2459585

Rozanolixizumab improved symptoms in people with generalised myasthenia gravis in the MycarinG clinical study: a Plain Language Summary of Publication

2025· article· en· W4409035768 on OpenAlexaff
Vera Bril, Kimiaki Utsugisawa, Tuan Vu, Marion Boehnlein, Maryam Gayfieva, Bernhard Greve, John Vissing

Bibliographic record

VenueFuture Neurology · 2025
Typearticle
Languageen
FieldMedicine
TopicMyasthenia Gravis and Thymoma
Canadian institutionsUniversity Health Network
Fundersnot available
KeywordsMyasthenia gravisMedicinePediatricsPsychologyPhysical therapyPhysical medicine and rehabilitationPsychiatry

Abstract

fetched live from OpenAlex

Plain Language SummaryWhat is this summary about?This is a summary of an article that describes the results of the MycarinG clinical study.Generalised myasthenia gravis is a rare, chronic (long-lasting) and fluctuating autoimmune disease that causes muscle weakness and fatigue (a sense of exhaustion). These symptoms can significantly impact the quality of life of people living with the disease, and their caregivers and families. Conventional treatments for myasthenia gravis do not always work well, and often have side effects that can limit their use, so there is a need for new and improved treatments. The MycarinG clinical study looked at whether taking rozanolixizumab once per week for 6 weeks was better at treating symptoms of generalised myasthenia gravis than a placebo.What were the results?The results of this 18-week study showed that symptoms of myasthenia gravis improved by a larger extent for people who took rozanolixizumab than for people who took placebo. The most common side effects with rozanolixizumab were headache, diarrhoea, fever and nausea.What do the results mean?These results mean that rozanolixizumab was an effective treatment for myasthenia gravis. The efficacy and safety of rozanolixizumab when taken for a longer period of time are being assessed in an extension of this study.How to say…Rozanolixizumab: Roh-ZAN-oh-lix-IZ-oo-mabMyasthenia gravis: My-as-THEEN-ee-a GRAH-vissPlacebo: Pluh-SEE-bohAcetylcholine: A-SIT-ile-KOH-leenQuality of life: Overall well-being including personal health, comfort and ability to participate in life events.Side effects: Unintended effects while taking a medication.Placebo: A medicine that looks and feels (and, if relevant, tastes) the same as the active treatment, but contains no active ingredients. A placebo may be used in clinical studies to ensure doctors are not biased when reporting their experience, by making sure they remain unaware of whether the patients are on treatment or not.Efficacy: The ability of a drug to produce a desired effect.Extension: An additional period after the observational period where patients can continue to take the medication if they want to. The extension period helps to understand the safety and efficacy of a treatment over a longer period of time than the initial clinical trial period.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.449

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.286
Teacher spread0.279 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFuture NeurologySame topicMyasthenia Gravis and ThymomaFrench-language works237,207